Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D05QJT
|
||||
| Former ID |
DNC014899
|
||||
| Drug Name |
GW274150
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Asthma [ICD10:J45] | Phase 2 | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C8H17N3O2S
|
||||
| Canonical SMILES |
CC(=NCCSCCC(C(=O)O)N)N
|
||||
| InChI |
1S/C8H17N3O2S/c1-6(9)11-3-5-14-4-2-7(10)8(12)13/h7H,2-5,10H2,1H3,(H2,9,11)(H,12,13)/t7-/m0/s1
|
||||
| InChIKey |
MOLOJNHYNHBPCW-ZETCQYMHSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Nitric oxide synthase, inducible | Target Info | Modulator | [2] | |
| BioCyc Pathway | Citrulline-nitric oxide cycle | ||||
| KEGG Pathway | Arginine biosynthesis | ||||
| Arginine and proline metabolism | |||||
| Metabolic pathways | |||||
| Calcium signaling pathway | |||||
| HIF-1 signaling pathway | |||||
| Peroxisome | |||||
| Salmonella infection | |||||
| Pertussis | |||||
| Leishmaniasis | |||||
| Chagas disease (American trypanosomiasis) | |||||
| Toxoplasmosis | |||||
| Amoebiasis | |||||
| Tuberculosis | |||||
| Pathways in cancer | |||||
| Small cell lung cancer | |||||
| NetPath Pathway | IL1 Signaling Pathway | ||||
| IL2 Signaling Pathway | |||||
| Pathway Interaction Database | IL12-mediated signaling events | ||||
| Alpha9 beta1 integrin signaling events | |||||
| ATF-2 transcription factor network | |||||
| IL23-mediated signaling events | |||||
| Signaling mediated by p38-alpha and p38-beta | |||||
| HIF-1-alpha transcription factor network | |||||
| Reactome | ROS production in response to bacteria | ||||
| Nitric oxide stimulates guanylate cyclase | |||||
| WikiPathways | Type II interferon signaling (IFNG) | ||||
| Spinal Cord Injury | |||||
| AGE/RAGE pathway | |||||
| Effects of Nitric Oxide | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00370435) Study Of 90mg Of GW274150 In Subjects Over 50 Years, Who Have Rheumatoid Arthritis (RA). U.S. National Institutes of Health. | ||||
| REF 2 | Br J Pharmacol. 2005 Jun;145(3):301-12.GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.